A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
DDY391: DDY391 dose level 1 DDY391 dose level 2 DDY391 dose level 3
Placebo: Matching Placebo
Study summary
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection for Phase 3.
Eligibility
Primary outcome measure(s)
- Part A and B: Change from baseline in ESSDAI score — Baseline, Week 24
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a validated tool for assessing disease activity in SjD. Score range is 0-123. Higher scores on the ESSDAI scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status. - Part C: Change from baseline in ESSPRI — Baseline, Week 24
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is a validated disease outcome measure for SjD. It consists of three domains of dryness, pain, and fatigue. The participant will assess severity of symptoms they experienced over the last 14 days on a single 0-10 numerical rating scale for each of the three domains. The ESSPRI score is defined as the mean of scores from the three scales: (dryness + pain + fatigue) /3. The total ESSPRI score ranges from 0 (no symptoms) to 10 (maximal symptom severity).
Trial sites (31)
| Facility | City | Region | Status |
|---|---|---|---|
| Arizona Arthritis and Rheumatology Associates PLLC | Avondale | Arizona | Recruiting |
| Clinical Res Of W Florida | Clearwater | Florida | Recruiting |
| Clinical Research of West Florida Inc | Tampa | Florida | Recruiting |
| Chicago Clinical Research Inst | Chicago | Illinois | Recruiting |
| Willow Rheumatology Wellness | Willowbrook | Illinois | Recruiting |
| RAO Research LLC | Oklahoma City | Oklahoma | Recruiting |
| Altoona Center for Clin Res | Duncansville | Pennsylvania | Recruiting |
| Rheumatology Specialty Center - Willow Grove Office | Willow Grove | Pennsylvania | Recruiting |
| Shelby Research LLC | Memphis | Tennessee | Recruiting |
| Stryde Research-Allen Arthritis | Allen | Texas | Recruiting |
| Novel Research LLC | Bellaire | Texas | Recruiting |
| Arthritis Care of Texas | Corpus Christi | Texas | Recruiting |
| Novartis Investigative Site | Southport | Queensland | Recruiting |
| Novartis Investigative Site | Nedlands | Western Australia | Recruiting |
| Novartis Investigative Site | Rimouski | Quebec | Recruiting |
| Novartis Investigative Site | Sherbrooke | Quebec | Recruiting |
| Novartis Investigative Site | Trois-Rivières | Quebec | Recruiting |
| Novartis Investigative Site | Hefei | Anhui | Recruiting |
| Novartis Investigative Site | Nanjing | Jiangsu | Recruiting |
| Novartis Investigative Site | Taiyuan | Shanxi | Recruiting |
| Novartis Investigative Site | Beijing | China | Recruiting |
| Novartis Investigative Site | Beijing | China | Recruiting |
| Novartis Investigative Site | Bogota | Cundinamarca | Recruiting |
| Novartis Investigative Site | Paris | France | Recruiting |
| Novartis Investigative Site | Kaposvár | Hungary | Recruiting |
| Novartis Investigative Site | Kfar Saba | Israel | Recruiting |
| Novartis Investigative Site | Petah Tikva | Israel | Recruiting |
| Novartis Investigative Site | Ramat Gan | Israel | Recruiting |
| Novartis Investigative Site | Tel Aviv | Israel | Recruiting |
| Novartis Investigative Site | Tsrifin | Israel | Recruiting |
| Novartis Investigative Site | Groningen | Provincie Groningen | Recruiting |
More Novartis Pharmaceuticals trials in Australia
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07737743 on ClinicalTrials.gov ↗ ← All trials in Australia